CLEC3B and cardiovascular disorder: More recently, a 2018 biomarker analysis of the Framingham cohort in the US has shown that reduced circulating levels of Tetranectin (CLEC3B) are significantly associated with all‐cause mortality and with cardiovascular disease death27.